125 related articles for article (PubMed ID: 38282187)
1. Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and Progression of Liver Hepatocellular Carcinoma.
Huang FD; Zhong YP; Sun GY; Xu QJ; Xing ZY; Chen KH; Liao LS; Dong MY
Dig Dis Sci; 2024 Mar; 69(3):1035-1054. PubMed ID: 38282187
[TBL] [Abstract][Full Text] [Related]
2. FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma.
Hou Y; Li J; Yu A; Deng K; Chen J; Wang Z; Huang L; Ma S; Dai X
Int J Med Sci; 2023; 20(7):918-932. PubMed ID: 37324186
[No Abstract] [Full Text] [Related]
3. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
4. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.
Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q
J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368
[TBL] [Abstract][Full Text] [Related]
5. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
Jin W; Wang G; Dong M; Wang X
Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma.
He D; Zhang X; Tu J
Cancer Med; 2020 Dec; 9(23):8782-8800. PubMed ID: 32978904
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
[TBL] [Abstract][Full Text] [Related]
10. Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma.
Chen G; Mo S; Yuan D
Biomed Res Int; 2021; 2021():9911784. PubMed ID: 34195286
[TBL] [Abstract][Full Text] [Related]
11. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
12. Integrative Multi-Omics Analysis of Identified Ferroptosis-Marker RPL8 as a Candidate Oncogene Correlates with Poor Prognosis and Immune Infiltration in Liver Cancer.
Fan S; Zhang S; Kong D; Wang H; Shi Y; Wang Z; Zheng H
Comb Chem High Throughput Screen; 2023; 26(7):1298-1310. PubMed ID: 36017842
[TBL] [Abstract][Full Text] [Related]
13. The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics.
Qin P; Huang H; Wang J; Jiang T; Zeng N; Wang Q; He Y; Zhou Y
Med Oncol; 2023 Aug; 40(9):276. PubMed ID: 37612479
[TBL] [Abstract][Full Text] [Related]
14. Exploring the diagnostic value, prognostic value, and biological functions of NPC gene family members in hepatocellular carcinoma based on a multi-omics analysis.
Chen K; Zhang X; Peng H; Huang F; Sun G; Xu Q; Liao L; Xing Z; Zhong Y; Fang Z; Liao M; Luo S; Chen W; Dong M
Funct Integr Genomics; 2023 Aug; 23(3):264. PubMed ID: 37541978
[TBL] [Abstract][Full Text] [Related]
15. Identification and Validation of DEPDC1B as an Independent Early Diagnostic and Prognostic Biomarker in Liver Hepatocellular Carcinoma.
Fan X; Wen J; Bao L; Gao F; Li Y; He D
Front Genet; 2021; 12():681809. PubMed ID: 35095994
[TBL] [Abstract][Full Text] [Related]
16. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.
He A; Huang Z; Wang J; Lu H; Zhang R; Wu L; Feng Q
Dis Markers; 2022; 2022():3968303. PubMed ID: 35855852
[TBL] [Abstract][Full Text] [Related]
18. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
[TBL] [Abstract][Full Text] [Related]
19. Integrated Bioinformatics and Experimental Analysis Identified TRIM28 a Potential Prognostic Biomarker and Correlated with Immune Infiltrates in Liver Hepatocellular Carcinoma.
Han J; Wang Y; Zhou H; Ai S; Wan D
Comput Math Methods Med; 2022; 2022():6267851. PubMed ID: 36238495
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.
Zong RQ; Zhang HY; Li XY; Li YR; Chen Y
Genet Res (Camb); 2022; 2022():7067743. PubMed ID: 36262249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
